Denna sida har översatts automatiskt och översättningens korrekthet kan inte garanteras. Vänligen se engelsk version för en källtext.

Volrustomig Priming Regimens Exploratory Phas II Platform Study (eVOLVE-01)

28 september 2026 uppdaterad av: AstraZeneca

En öppen fas II-studie för att utvärdera säkerhet, tolerabilitet, farmakokinetik, immunogenicitet och antitumöraktivitet hos Volrustomig-primingregimer i kombination med andra anticancermedel hos deltagare med solida tumörer (eVOLVE-01)

Purpose of this study is to assess the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of volrustomig in combination with other anticancer drugs in participants with specified solid tumors.

Studieöversikt

Detaljerad beskrivning

This Phase II, platform, open-label, multicenter study will evaluate the efficacy, safety, and tolerability of volrustomig in combination with anticancer drugs in various solid tumor types.

This platform study currently includes 2 substudies:

Substudy 1: metastatic non-small cell lung cancer (mNSCLC) (non-squamous [NSQ]). Participants will be randomized in two treatment arms: Arm 1A and Arm 1B.

Substudy 2: mNSCLC (squamous [SQ] or NSQ). Participants will enroll to the Arm 2A only.

All arms will test a volrustomig dosing in combination with chemotherapy.

Studietyp

Interventionell

Inskrivning (Faktisk)

194

Fas

  • Fas 2

Kontakter och platser

Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.

Studieorter

      • Bois-Guillaume, Frankrike, 76031
        • Research Site
      • Caen, Frankrike, 14076
        • Research Site
      • Dijon, Frankrike, 21079
        • Research Site
      • Montpellier, Frankrike, 34070
        • Research Site
    • California
      • Los Angeles, California, Förenta staterna, 90067
        • Research Site
    • North Carolina
      • Chapel Hill, North Carolina, Förenta staterna, 27514
        • Research Site
      • Batumi, Georgien, 6010
        • Research Site
      • Tbilisi, Georgien, 0144
        • Research Site
      • Tbilisi, Georgien, 0112
        • Research Site
      • Tbilisi, Georgien, '0159
        • Research Site
      • Tbilisi, Georgien, 186
        • Research Site
      • Tbilisi, Georgien, 0114
        • Research Site
      • Athens, Grekland, 115 27
        • Research Site
      • Athens, Grekland, 12462
        • Research Site
      • Elaiones, Grekland, 546 23
        • Research Site
      • Piraeus, Grekland, 185 47
        • Research Site
      • Thessaloniki, Grekland, 57001
        • Research Site
      • Genoa, Italien, 16132
        • Research Site
      • Meldola, Italien, 47014
        • Research Site
      • Milan, Italien, 20133
        • Research Site
      • Naples, Italien, 80131
        • Research Site
      • Orbassano, Italien, 10043
        • Research Site
      • Perugia, Italien, 06132
        • Research Site
      • Rozzano, Italien, 20089
        • Research Site
      • Udine, Italien, 33100
        • Research Site
      • Verona, Italien, 37134
        • Research Site
      • Beijing, Kina, 100730
        • Research Site
      • Hangzhou, Kina, 310014
        • Research Site
      • Jinan, Kina, 250013
        • Research Site
      • Yantai, Kina, 264000
        • Research Site
      • Zhengzhou, Kina, 450000
        • Research Site
      • Kuala Lumpur, Malaysia, 59100
        • Research Site
      • Kuching, Malaysia, 93586
        • Research Site
      • Perai, Malaysia, 13700
        • Research Site
      • Lisbon, Portugal, 1649-035
        • Research Site
      • Lisbon, Portugal, 1169-050
        • Research Site
      • Lisbon, Portugal, 1400-038
        • Research Site
      • Porto, Portugal, 4099-001
        • Research Site
      • Cluj-Napoca, Rumänien, 400641
        • Research Site
      • Craiova, Rumänien, 200542
        • Research Site
      • Floreşti, Rumänien, 407280
        • Research Site
      • Geneva, Schweiz, 1205
        • Research Site
      • Lausanne, Schweiz, 1011
        • Research Site
      • Winterthur, Schweiz, 8401
        • Research Site
      • Zurich, Schweiz, 8091
        • Research Site
      • Belgrade, Serbien, 11000
        • Research Site
      • A Coruña, Spanien, 15009
        • Research Site
      • Alcorcón, Spanien, 28922
        • Research Site
      • Barcelona, Spanien, 08041
        • Research Site
      • Madrid, Spanien, 28041
        • Research Site
      • Málaga, Spanien, 29004
        • Research Site
      • Pamplona, Spanien, 31008
        • Research Site
      • Santander, Spanien, 39008
        • Research Site
      • Santiago de Compostela, Spanien, 15706
        • Research Site
      • Valencia, Spanien, 46026
        • Research Site
      • Valencia, Spanien, 46015
        • Research Site
      • Seongnam, Sydkorea, 13620
        • Research Site
      • Seoul, Sydkorea, 03722
        • Research Site
      • Suwon, Sydkorea, 16247
        • Research Site
      • Changhua, Taiwan, 50006
        • Research Site
      • New Taipei City, Taiwan, 23561
        • Research Site
      • Taipei, Taiwan, 106
        • Research Site
      • Taipei, Taiwan, 110
        • Research Site

Deltagandekriterier

Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.

Urvalskriterier

Åldrar som är berättigade till studier

18 år till 130 år (Vuxen, Äldre vuxen)

Tar emot friska volontärer

Nej

Kön som är behöriga för studier

Allt

Beskrivning

Key Inclusion Criteria:

  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 with no deterioration.
  • Life expectancy greater than or equal to (>=) 12 weeks.
  • Adequate organ and bone marrow function.
  • Body weight greater than (>) 35 kilograms (kg) at screening and at randomization.
  • Histologically or cytologically documented NSQ NSCLC in substudy 1 and SQ or NSQ mNSCLC in substudy 2.
  • Absence of sensitizing epidermal growth factor receptor (EGFR) mutations.
  • Absence of documented tumor genomic alteration results from tests conducted as part of standard local practice in any other actionable driver oncogenes for which there are locally approved targeted 1L therapies.
  • At least one measurable lesion not previously irradiated that can be accurately measured at baseline as >= 10 millimeter (mm) in the longest diameter.

Key Exclusion Criteria:

  • Spinal cord compression.
  • History of primary active immunodeficiency.
  • Active or prior documented autoimmune or inflammatory disorders.
  • Mixed small-cell lung cancer and NSCLC histology or sarcomatoid variant.
  • Brain metastases unless asymptomatic, stable, and not requiring steroids for at least 14 days prior to start of study intervention. A minimum of 2 weeks must have elapsed between the end of radiation therapy and study enrollment.
  • Prior chemotherapy or any other systemic therapy for Stage IV NSCLC. Participants who have received prior platinum-containing adjuvant, neoadjuvant, or definitive chemoradiation for local disease are eligible, provided that progression has occurred greater (>) 12 months from end of last therapy.

Studieplan

Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.

Hur är studien utformad?

Designdetaljer

  • Primärt syfte: Behandling
  • Tilldelning: Randomiserad
  • Interventionsmodell: Parallellt uppdrag
  • Maskning: Ingen (Open Label)

Vapen och interventioner

Deltagargrupp / Arm
Intervention / Behandling
Experimentell: Substudy 1: Arm 1A: Volrustomig dose regimen 1 + Carboplatin and Pemetrexed

Volrustomig priming dose followed by volrustomig dosing regimen 1 in combination with carboplatin and pemetrexed.

Participants will receive volrustomig via intravenous (IV) infusion.

Andra namn:
  • MEDI5752

Participants will receive carboplatin via IV infusion.

Participants will receive pemetrexed via IV infusion.

Experimentell: Substudy 1: Arm 1B: Volrustomig dose regimen 2 + Carboplatin and Pemetrexed

Volrustomig priming dose followed by volrustomig dosing regimen 2 in combination with carboplatin and pemetrexed.

Participants will receive volrustomig via intravenous (IV) infusion.

Andra namn:
  • MEDI5752

Participants will receive carboplatin via IV infusion.

Participants will receive pemetrexed via IV infusion.

Experimentell: Substudy 2: Arm 2A: Volrustomig dose regimen 2 +Ramucirumab + Carboplatin + Pemetrexed or Paclitaxel

Volrustomig priming dose followed by volrustomig dosing regimen 2 in combination with ramucirumab and histology-specific chemotherapy (carboplatin+ either pemetrexed or paclitaxel).

Participants will receive volrustomig via intravenous (IV) infusion.

Andra namn:
  • MEDI5752

Participants will receive carboplatin via IV infusion.

Participants will receive pemetrexed via IV infusion.

Participants will receive ramucirumab via IV infusion.

Participants will receive paclitaxel via IV infusion.

Vad mäter studien?

Primära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Number of Participants with Adverse Events (AEs) and Serious Adverse Events (SAEs)
Tidsram: From screening (Days -28 to Day -1) up to 2 year 10 months

The safety and tolerability of volrustomig in combination with other anticancer drugs in participants with specified solid tumors will be assessed.

From screening (Days -28 to Day -1) up to 2 year 10 months
Confirmed Objective Response rate (ORR)
Tidsram: Up to 2 year 10 months

ORR is defined as the percentage of participants who have a confirmed complete response (CR) or confirmed partial response (PR), as per Response Evaluation Criteria in Solid Tumors, Version 1.1 (RECIST 1.1).

Up to 2 year 10 months

Sekundära resultatmått

Resultatmått
Åtgärdsbeskrivning
Tidsram
Disease Control Rate (DCR)
Tidsram: Up to 2 year 10 months

DCR is defined as the percentage of participants who have a CR or PR or who have stable disease (SD) after the date of randomization or first dose.

Up to 2 year 10 months
Duration of Response (DOR)
Tidsram: Up to 2 year 10 months

DOR is defined as the time from the date of first documented response until the date of documented progression or death due to any cause (in the absence of progression).

Up to 2 year 10 months
Progression Free Survival (PFS)
Tidsram: Up to 2 year 10 months

PFS is defined as the time from randomization or first dose until radiological progression or death due to any cause (in the absence of progression).

Up to 2 year 10 months
Overall Survival (OS)
Tidsram: Up to 2 year 10 months

OS is defined as the time from randomization or first dose until the date of death due to any cause.

Up to 2 year 10 months
Serum Concentration of Volrustomig
Tidsram: Up to 2 year 10 months

The serum concentrations volrustomig alone and when used in combination with other anticancer agents in participants with pre-specified solid tumors will be assessed.

Up to 2 year 10 months
Trough concentration (Ctrough)
Tidsram: Up to 2 year 10 months

The trough concentrations volrustomig alone and when used in combination with other anticancer agents in participants with pre-specified solid tumors will be assessed.

Up to 2 year 10 months
Maximum Observed Concentration (Cmax)
Tidsram: Up to 2 year 10 months

The serum concentrations volrustomig alone and when used in combination with other anticancer agents in participants with pre-specified solid tumors will be assessed.

Up to 2 year 10 months
Area Under the Curve (AUC)
Tidsram: Up to 2 year 10 months

The AUC concentrations of volrustomig alone and when used in combination with other anticancer agents in participants with pre-specified solid tumors will be assessed.

Up to 2 year 10 months
Number of Participants with Positive Antidrug Antibodies (ADAs)
Tidsram: Up to 2 year 10 months

The incidence of ADAs against volrustomig or other anticancer agents in serum will be assessed.

Up to 2 year 10 months

Samarbetspartners och utredare

Det är här du hittar personer och organisationer som är involverade i denna studie.

Sponsor

Studieavstämningsdatum

Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.

Studera stora datum

Studiestart (Faktisk)

27 augusti 2024

Primärt slutförande (Beräknad)

30 juli 2027

Avslutad studie (Beräknad)

30 juli 2027

Studieregistreringsdatum

Först inskickad

4 juni 2024

Först inskickad som uppfyllde QC-kriterierna

4 juni 2024

Första postat (Faktisk)

7 juni 2024

Uppdateringar av studier

Senaste uppdatering publicerad (Faktisk)

29 september 2026

Senaste inskickade uppdateringen som uppfyllde QC-kriterierna

28 september 2026

Senast verifierad

1 september 2026

Mer information

Termer relaterade till denna studie

Plan för individuella deltagardata (IPD)

Planerar du att dela individuella deltagardata (IPD)?

JA

IPD-planbeskrivning

Qualified researchers can request access to anonymized individual patient-leveldata from AstraZeneca group of companies sponsored clinical trials via therequest portal Vivli.org. All requests will be evaluated as per the AZ disclosurecommitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure."Yes",indicates that AZ are accepting requests for IPD, but this does not mean allrequests will be approved.

Tidsram för IPD-delning

AstraZeneca will meet or exceed data availability as per the commitment smade to the EFPIA/PhRMA Data-Sharing Principles. For details of our timelines, please refer to our disclosure commitment athttps://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

Kriterier för IPD Sharing Access

When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure researchenvironmentVivli.org. A Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

IPD-delning som stöder informationstyp

  • STUDY_PROTOCOL
  • SAV

Läkemedels- och apparatinformation, studiedokument

Studerar en amerikansk FDA-reglerad läkemedelsprodukt

Ja

Studerar en amerikansk FDA-reglerad produktprodukt

Nej

Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .

Prenumerera